---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002859"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:11:34.679459+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Verastem secures up to $150M from Oberland Capital, repays Oxford loan, NDA accepted with June PDUFA

## Summary
- Initial $75M notes issued; net proceeds~$32.3M after repaying $42.7M Oxford loan; interest-only 6 years.
- Pro forma cash $128.6M including $7.5M equity placement (1.4M shares at $5.2931/share).
- FDA accepted NDA for avutometinib+defactinib in KRAS mutant LGSOC; PDUFA June 30, 2025; no AdCom planned.
- Revenue participation: Oberland gets 1% of first $100M annual net sales (max 2% if full $150M drawn).
- Strategic collaboration with IQVIA to support potential launch mid-2025.

## SEC filing metadata
- accession: 0001104659-25-002859
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925002859/0001104659-25-002859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925002859/tm253090d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002859
- JSON: https://secwatch.observer/filing/0001104659-25-002859.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.